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Abstract
Neuraminidase-1 (NEU1) is the predominant sialidase expressed in human airway epithelia and
lung microvascular endothelia where it mediates multiple biological processes. We tested
whether the NEU1-selective sialidase inhibitor, C9-butyl-amide-2-deoxy-2,3-dehydro-Nacetylneuraminic acid (C9-BA-DANA), inhibits one or more established NEU1-mediated
bioactivities in human lung cells. We established the IC50 values of C9-BA-DANA for total
sialidase activity in human airway epithelia, lung microvascular endothelia and lung fibroblasts
to be 3.74 µM, 13.0 µM and 4.82 µM, respectively. In human airway epithelia, C9-BA-DANA
dose-dependently inhibited flagellin-induced, NEU1-mediated mucin-1 ectodomain
desialylation, adhesiveness for Pseudomonas aeruginosa and shedding. In lung microvascular
endothelia, C9-BA-DANA reversed NEU1-driven restraint of cell migration into a wound and
disruption of capillary-like tube formation. NEU1 and its chaperone/transport protein, protective
protein/cathepsin A (PPCA), were differentially expressed in these same cells. Normalized
NEU1 protein expression correlated with total sialidase activity whereas PPCA expression did
not. In contrast to eukaryotic sialidases, C9-BA-DANA exerted far less inhibitory activity for
three selected bacterial neuraminidases (IC50 > 800 µM). Structural modeling of the four human
sialidases and three bacterial neuraminidases revealed a loop between the seventh and eighth
strands of the β-propeller fold, that in NEU1, was substantially shorter than that seen in the six
other enzymes. Predicted steric hindrance between this loop and C9-BA-DANA could explain its
selectivity for NEU1. Finally, pretreatment of mice with C9-BA-DANA completely protected
against flagellin-induced increases in lung sialidase activity. Our combined data indicate that C9BA-DANA inhibits endogenous and ectopically expressed sialidase activity and established
NEU1-mediated bioactivities in human airway epithelia, lung microvascular endothelia, and
fibroblasts in vitro and murine lungs in vivo.
Keywords: lung, NEU1, neuraminidase, PPCA, sialidase

Introduction
The surface of all eukaryotic cells is sialylated (Varki and Varki 2007; Cohen and Varki 2010).
Glycoproteins and glycolipids expressed on the cell surface contain oligosaccharide chains
whose outermost positions can terminate with sialic acid. The sialylation state of these surface
structures is regulated, at least in part, through sialidase catalytic activity (Monti et al. 2002;
Monti et al. 2010; Miyagi and Yamaguchi 2012). At least four human sialidases, also referred to
as neuraminidases, have been identified, NEU1, -2, -3 and -4 (Pshezhetsky et al. 1997; Miyagi et
al. 1999; Monti et al. 1999; Comelli et al. 2003). Superimposed on this complex biological

system, the human host also intimately interacts with numerous microbes that express their own
neuraminidases (Kim et al. 2011; Lewis and Lewis 2012). Whether eukaryotic sialidases
participate in specific biological processes is only now being explored and remains incompletely
understood. Sialidases reportedly influence growth factor and Toll-like receptor (TLR)
responsiveness and signaling (Hinek et al. 2008; Amith et al. 2009, 2010; Abdulkhalek et al.
2011, 2012; Feng et al. 2012; Lillehoj et al. 2012; Abdulkhalek and Szewczuk 2013), insulin
receptor activation and downstream signaling (Arabkhari et al. 2010; Dridi et al. 2013), elastin
fiber assembly (Hinek et al. 2006; Duca et al. 2007; Starcher et al. 2008), neuronal and muscle
cell differentiation (Fanzani et al. 2003; Kappagantula et al. 2014), angiogenesis (Lee et al.
2014), tumor cell biology and cancer metastasis (Miyagi et al. 2004, 2008; Uemura et al. 2009),
sperm function during fertilization (Ma et al. 2012) and bacterial pathogenesis (Chen et al. 2011;
Lillehoj et al. 2012). Our research group has focused on sialidase biology in three key cell types
within the human lung, i.e. airway epithelia (Lillehoj et al. 2012, 2015), microvascular
endothelia (Cross et al. 2012; Lee et al. 2014) and fibroblasts (Luzina et al. 2016). First, we
found that NEU1 was the predominant sialidase expressed in human airway epithelia, lung
microvascular endothelia and lung fibroblasts (Cross et al. 2012; Lillehoj et al. 2012; Luzina et
al. 2016). In human airway epithelial cells (HAECs), NEU1 impaired the migratory response
during wound repair (Luzina et al. 2016). In these same cells, we previously established
Pseudomonas aeruginosa (Pa)-derived flagellin as a signal-transducing ligand for
the ectodomain of mucin-1 (MUC1-ED) (Lillehoj et al. 2012, 2015), and more recently, found
that flagellin stimulation increases NEU1 association with and desialylation of the MUC1-ED
(Lillehoj et al. 2015). NEU1-mediated MUC1-ED desialylation increased both its adhesiveness
for flagellin-expressing Pa and its shedding from the HAEC surface (Lillehoj et al. 2015). In
human pulmonary microvascular endothelial cell (HPMEC)s, we found that NEU1 restrained
HPMEC migration into a wound (Cross et al. 2012; Lee et al. 2014) and disrupted HPMEC
capillary-like tube formation, i.e. in vitro angiogenesis (Lee et al. 2014). More recently, we
found that NEU1 expression is increased in lung tissues of patients with idiopathic pulmonary
fibrosis (IPF) (Luzina et al. 2016). In these reports, the impact of NEU1 on any specific cellular
response was established through prior siRNA-induced silencing of NEU1 and NEU1
overexpression (Cross et al. 2012; Lillehoj et al. 2012, 2015; Lee et al. 2014; Luzina et al. 2016).
However, such interventions would not be easily applied to human disease states in vivo.
NEU1 participates in multiple cellular functions (Monti et al. 2002, 2010; Miyagi and
Yamaguchi 2012). In most human cells, NEU1 is co-expressed with NEU2, -3 and -4 (Monti et
al. 2002, 2010; Miyagi and Yamaguchi 2012). Selective inhibition of NEU1 without off-target
cross-inhibition of any of the other three isoforms could provide insight into NEU1 function
and/or therapeutic possibilities for clinical conditions in which NEU1 might be overexpressed
and/or activated. Furthermore, NEU1-null mice display lung pathology and premature death,
thereby limiting studies of NEU1 function (Starcher et al. 2008). Most previous studies of
neuraminidase/sialidase inhibition have utilized recombinant enzymes in cell-free experimental
systems (Hata et al. 2008; Magesh et al. 2008, 2009; Zhang et al. 2013). In the current studies,
we tested the ability of the only reported NEU1-selective inhibitor, C9-butyl-amide-2-deoxy-2,3dehydro-N-acetylneuraminic acid (C9-BA-DANA) (Magesh et al. 2008), to inhibit NEU1mediated biological processes in both in vitro cell culture systems and in an intact murine model.

Although the overall sequence identities between individual members of the
neuraminidase/sialidase superfamily are low, each contains several conserved motifs and their
catalytic domains share a common six-bladed β-propeller fold architecture (Monti et al. 2002;
Miyagi and Yamaguchi 2012). Of the four known human sialidases, the crystal structure of only
NEU2 has been solved (Chavas et al. 2005). Several research groups have now designed and
synthesized pharmacologic inhibitors selective for both prokaryotic neuraminidases (von Itzstein,
2007) and eukaryotic sialidases (Magesh et al. 2006, 2008, 2009; Zhang et al. 2013). One
standard inhibitor, 2-deoxy-2,3-dehydro-N-acetylneuraminic acid (DANA), is a broad spectrum,
transition state analog inhibitor of viral, bacterial and mammalian neuraminidases/sialidases
(Meindi and Tuppy 1969; Burmeister et al. 1993). We designed and synthesized a series of 10 Namide-linked C9-modified analogs of DANA and tested their inhibitory activities against all four
human sialidases (Magesh et al. 2008). We found that the C9 N-amide-linked n-butyl derivative
of DANA, C9-BA-DANA, displayed ~15-fold increased inhibitory activity for NEU1 and >100fold decreased inhibitory activity for NEU2, -3 and -4 compared to that seen with unmodified
DANA. When C9-BA-DANA was tested against each human sialidase expressed in HEK-293
cells, it was >200-fold more selective for NEU1 (IC50 = 10 µM) versus NEU2, -3 and -4
(IC50 > 1000 µM). Whether C9-BA-DANA might inhibit bacterial neuraminidases has not been
tested. In the current studies, we have tested whether C9-BA-DANA might block endogenous
and/or ectopically expressed sialidase activity in human airway epithelia, lung microvascular
endothelia and/or lung fibroblasts, and inhibit established NEU1-driven biological processes in
two of these same three cell systems. The inhibitory activity for C9-BA-DANA against
prokaryotic neuraminidases in vitro, and total murine lung sialidase activity in vivo, was also
studied.

Results
C9-BA-DANA inhibits sialidase activity in HAECs
We previously established NEU1 as the predominant sialidase expressed in HAECs (Lillehoj et
al. 2012) and defined its participation in multiple bioactivities in these same cells (Lillehoj et al.
2012, 2015; Luzina et al. 2016). To better control NEU1-mediated events in the airway
epithelium, we asked whether the NEU1-selective inhibitor, C9-BA-DANA (Magesh et al.
2008), might inhibit sialidase activity in A549 cells. A fixed amount of A549 cellular protein or a
fixed number of A549 cells were assayed for sialidase activity for the fluorogenic substrate, 2′(4-methylumbelliferyl)-α-d-N-acetylneuraminic acid (4-MU-NANA), in the presence of
increasing concentrations of C9-BA-DANA (Figure (Figure1A).1A). C9-BA-DANA, at
concentrations ≥1.34 µM, dose-dependently inhibited A549 cell sialidase activity with an IC50 of
3.74 µM.

Fig. 1. C9-BA-DANA inhibits sialidase activity and flagellin-stimulated, NEU1-mediated
MUC1-ED desialylation, increases in adhesiveness for Pa, and shedding in HAECs. (A) A fixed
amount of A549 cellular protein (0.63 mg) or a fixed number of A549 cells (106 cells/reaction)
were assayed for sialidase activity for the fluorogenic substrate, 4-MU-NANA, in the presence of
increasing concentrations of C9-BA-DANA. Vertical bars represent mean (±SE) sialidase
activity expressed as arbitrary fluorescence units/mg protein (left Y-axis) or arbitrary
fluorescence units/106 cells (right Y-axis) (n = 2/4). *, decreased sialidase activity in the presence
versus absence of C9-BA-DANA at P < 0.05. (B) The positive control asialofetuin and the
negative control fetuin (1.0 µg of each) were processed for PNA lectin blotting. IB, immunoblot.
Molecular weight in kDa indicated on the left. (C-F) A549 cells were incubated for 30 min (C–
E) or 24 h (F) with 10 ng/mL of Pa flagellin or medium alone in the presence of increasing
concentrations of C9-BA-DANA (C–F) or 100 μM of DANA (F). (C) The cells were lysed and
the lysates were incubated with PNA-agarose and the PNA-binding proteins processed for
MUC1-ED immunoblotting. PD, pull-down; IB, immunoblot. Molecular weight in kDa indicated
on the left. (D) Densitometric analyses of the blots in (C). Vertical bars represent mean (±SE)
PNA-bound MUC1-ED signal (n = 3). *, increased MUC1-ED desialylation in flagellin-treated
versus untreated cells at P < 0.05. **, decreased MUC1-ED desialylation in C9-BA-DANA
treated versus untreated cells at P < 0.05. (E) The cells were fixed, washed and incubated for 30
min with Pa (MOI = 100). Nonadherent Pa was removed by washing, and CFUs of cell-bound Pa
quantified. Vertical bars represent mean (±SE) Pa CFUs/well (n = 9). *, increased Pa adhesion to
flagellin-treated versus untreated cells at P < 0.05. **, decreased Pa adhesion to C9-BA-DANA

treated versus untreated cells at P < 0.05. (F) The cells were cultured for 24 h after which
MUC1-ED levels in supernates were quantified by ELISA and normalized to total cellular
protein. Vertical bars represent mean (±SE) shed MUC1-ED normalized to total cellular protein
(n = 3/12). *, increased shed MUC1-ED in supernates of flagellin-treated versus untreated cells
at P < 0.05. **, decreased shed MUC1-ED in supernates in C9-BA-DANA treated
versus untreated cells at P < 0.05. (G) A549 cells were cultured for 24 h in the presence of 100
µM of C9-BA-DANA or medium alone after which MTT was added for an additional 4 h. After
DMSO solubilization, the A490 was measured. Vertical bars represent the mean (±SE) A490
(n = 3). Each result is representative of ≥3 independent experiments.

C9-BA-DANA inhibits flagellin-stimulated, NEU1-mediated MUC1-ED
desialylation, increases in adhesiveness for Pa, and shedding
We previously demonstrated that Pa-derived flagellin is a ligand for the MUC1-ED (Lillehoj et
al. 2012, 2015) and that its engagement of this receptor increases NEU1 association with and
desialylation of MUC1-ED (Lillehoj et al. 2015). Furthermore, NEU1-mediated desialylation of
MUC1-ED renders it hyperadhesive for Pa and increases its shedding from the cell surface
(Lillehoj et al. 2015). First, we asked whether C9-BA-DANA could inhibit MUC1-ED
desialylation as measured by quantitative peanut agglutinin (PNA) lectin blotting. The PNA
lectin probe was validated using asialofetuin and fetuin as nonsialylated positive and sialylated
negative controls, respectively (Figure (Figure1B).1B). As anticipated, PNA recognized
asialofetuin (lane 2) but not fetuin (lane 1). Flagellin increased PNA recognition of MUC1-ED
by 2.2-fold and C9-BA-DANA at concentrations ≥10 µM dose-dependently protected against
this desialylation (Figure (Figure1C,D).1C,D). Although C9-BA-DANA at 1.0 µM diminished
MUC1-ED desialylation, this decrease did not achieve statistical significance (P = 0.16) (Figure
(Figure1D).1D). C9-BA-DANA at 100 µM completely reversed the flagellin-induced MUC1-ED
desialylation. Since C9-BA-DANA clearly inhibited MUC1-ED desialylation, we asked whether
it might also diminish flagellin-induced increases in Pa adhesion to MUC1-ED-expressing cells
(Figure (Figure1E)1E) and/or MUC1-ED shedding (Figure (Figure1F).1F). As anticipated,
flagellin increased Pa adhesion by 3.5-fold, and again, C9-BA-DANA at concentrations ≥10 µM
dose-dependently protected against increases in Pa adhesion with almost complete reversal at
100 µM (Figure (Figure1E).1E). Similarly, flagellin increased MUC1-ED shedding 3.2-fold and
C9-BA-DANA at concentrations ≥10 µM dose-dependently decreased shedding (Figure
(Figure1F).1F). However, C9-BA-DANA at 100 µM only diminished flagellin-provoked
shedding by 46.8% (Figure (Figure1F).1F). We asked whether the more broad spectrum, less
specific sialidase inhibitor, DANA, might more effectively decrease MUC1-ED shedding
through its ability to target sialidase(s) other than NEU1. DANA, at an equivalent concentration,
inhibited shedding by 52.7%, comparable to the inhibition seen with the more NEU1-selective
inhibitor, C9-BA-DANA (Figure (Figure1F).1F). No difference in viability was detected
between A549 cells cultured for 24 h in the presence of 100 µM of C9-BA-DANA or medium
alone (Figure (Figure1G),1G), indicating that none of the above results could be ascribed to
cytotoxic effects of the compound. These combined data indicate that C9-BA-DANA dosedependently protected versus flagellin-stimulated MUC1-ED desialylation, which in turn,
counter-regulated increases in both Pa adhesion and MUC1-ED shedding.

C9-BA-DANA inhibits sialidase activity in HPMECs
We previously found NEU1 to be the predominant sialidase expressed in HPMECs (Cross et al.
2012). We asked whether C9-BA-DANA might inhibit HPMEC sialidase activity. A fixed
amount of HPMEC protein or a fixed number of HPMECs were assayed for sialidase activity in
the 4-MU-NANA assay in the presence of increasing concentrations of C9-BA-DANA (Figure
(Figure2A).2A). C9-BA-DANA, at concentrations ≥2.67 µM, dose-dependently inhibited
HPMEC sialidase activity with an IC50 of 13.0 µM.

Fig. 2. C9-BA-DANA inhibits sialidase activity and counteracts NEU1-mediated inhibition of
HPMEC migration and capillary-like tube formation. (A) A fixed amount of HPMEC protein
(0.71 mg) or a fixed number of HPMECs (106 cells/reaction) were assayed for sialidase activity
for 4-MU-NANA in the presence of increasing concentrations of C9-BA-DANA. Vertical bars
represent mean (±SE) sialidase activity expressed as arbitrary fluorescence units/mg protein (left
Y-axis) or arbitrary fluorescence units/106 cells (right Y-axis) (n = 2/4). *, decreased sialidase
activity in the presence versus absence of C9-BA-DANA at P < 0.05. (B–E) HPMECs and
HPMECs infected with Ad-NEU1 or Ad-GFP (MOI = 100) were cultured for 48 h. (B, C) A
single wound was made across the diameter of each confluent monolayer, after which the
wounded monolayers were incubated for 24 h in the absence or presence of 134 µM of C9-BADANA and photomicrographs taken. (C) The number of migrating HPMECs was calculated

using ImageJ software for comparison with that observed in the same wounded monolayer at 0 h,
as a measure of migration into the wound. Each vertical bar represents mean (±SE) migration
into the wound (n = 3/5). *, decreased migration in Ad-NEU1 infected versus Ad-GFP infected
cells at P < 0.05. **, increased migration in C9-BA-DANA treated, Ad-NEU1 infected vs.
untreated, Ad-NEU1 infected cells at P < 0.05. (D) HPMECs were seeded on Matrigel-coated
wells at 1.5 × 104 cells/well, and after 6 h, tubular structures photographed. (E) Segments of
capillary-like tubes per HPF were counted. Vertical bars represent mean (±SE) segments/HPF
(n = 7). *, decreased tube formation in Ad-NEU1 infected versus Ad-GFP infected cells at P
< 0.05. **, increased tube formation in C9-BA-DANA treated, Ad-NEU1 infected versus
untreated, Ad-NEU1 infected cells at P < 0.05. (F) HPMECs were cultured for 24 h in the
presence of 100 µM of C9-BA-DANA or medium alone after which MTT was added for an
additional 4 h. After DMSO solubilization, the A490 was measured. Vertical bars represent mean
(±SE) A490 (n = 3). Each result is representative of ≥3 independent experiments. This figure is
available in black and white in print and in color at Glycobiology online.

C9-BA-DANA counteracts NEU1-mediated inhibition of HPMEC migration and
capillary-like tube formation
We previously reported that NEU1 overexpression in HPMECs restrains their migration into a
wound (Cross et al. 2012; Lee et al. 2014) and disrupts in vitro angiogenesis (Lee et al. 2014).
HPMECs and HPMECs infected with adenovirus (Ad) encoding human NEU1 (Ad-NEU1) or
green fluorescent protein (Ad-GFP) as a control, were studied in the presence or absence of C9BA-DANA, for migration in wounding assays (Figure (Figure2B,C)2B,C) and capillary-like tube
formation on Matrigel (Figure (Figure2D,E).2D,E). In the uninfected HPMECs, C9-BA-DANA
did not alter cell migration compared to simultaneous medium controls (Figure
(Figure2B,C).2B,C). NEU1 overexpression diminished HPMEC migration into a wound by
58.6% and the presence of C9-BA-DANA reversed the NEU1-driven inhibition by 84.2%
(Figure (Figure2B,C).2B,C). Similarly, NEU1 overexpression decreased capillary-like tube
formation by 39.7% and C9-BA-DANA reversed the NEU1-mediated inhibition by 70.0%
(Figure (Figure2D,E).2D,E). No difference in viability was detected between HPMECs cultured
for 24 h in the presence of 100 µM of C9-BA-DANA or medium alone (Figure (Figure2F).2F).
These combined data indicate that C9-BA-DANA protects against NEU1-mediated inhibition of
both the HPMEC migratory response to injury and capillary-like tube formation or in vitro
angiogenesis.

C9-BA-DANA inhibits sialidase activity in HLFs
We recently reported that human lung fibroblasts (HLFs) express NEU1, and NEU1 expression
is increased in fibroblasts obtained from the lungs of IPF patients (Luzina et al. 2016). To test
whether C9-BA-DANA inhibits sialidase activity in HLFs, a fixed amount of HLF protein or a
fixed number of HLFs were assayed for sialidase activity for the fluorogenic substrate, 4-MUNANA, in the presence of increasing concentrations of C9-BA-DANA (Figure (Figure3A).3A).
C9-BA-DANA, at concentrations ≥1.34 µM, dose-dependently inhibited HLF sialidase activity
with an IC50 of 4.82 µM. No difference in viability was detected between HLFs cultured for 24 h
in the presence of 100 µM of C9-BA-DANA or medium alone (Figure (Figure33B).

Fig. 3. C9-BA-DANA inhibits sialidase activity in HLFs. (A) A fixed amount of HLF protein
(1.00 mg) or a fixed number of HLFs (106 cells/reaction) were assayed for sialidase activity for
4-MU-NANA in the presence of increasing concentrations of C9-BA-DANA. Vertical bars
represent mean (±SE) sialidase activity expressed as arbitrary fluorescence units/mg protein (left
Y-axis) or arbitrary fluorescence units/106 cells (right Y-axis) (n = 2). *, decreased sialidase
activity in the presence versus absence of C9-BA-DANA at P < 0.05. (B) HLFs were cultured
for 24 h in the presence of 100 µM of C9-BA-DANA or medium alone after which MTT was
added for an additional 4 h. After DMSO solubilization, the A490 was measured. Vertical bars
represent mean (±SE) A490 (n = 3). Each result is representative of three independent
experiments.

Differential expression of NEU1 and PPCA in HAECs, HPMECs and HLFs
We found that resting baseline total sialidase activities for the 4-MU-NANA substrate, expressed
as mean ± SE arbitrary fluorescence units/mg cellular protein, were 7866 ± 206 in A549 cells
(Figure (Figure1A),1A), 12,345 ± 51.9 in HPMECs (Figure (Figure2A)2A) and 2384 ± 9.95 in
HLFs (Figure (Figure3A).3A). Also resting baseline total sialidase activities, expressed as
mean ± SE arbitrary fluorescence units/106 cells, were 5000 ± 128 in A549 cells (Figure
(Figure1A),1A), 8705 ± 36.6 in HPMECs (Figure (Figure2A)2A) and 2386 ± 9.97 in HLFs
(Figure (Figure3A).3A). The IC50 values for the NEU1 inhibitor, C9-BA-DANA, for sialidase
activity in each of these same three cell types were 3.74, 13.0 and 4.82 µM, respectively (Figures
(Figures1A,1A, A,2A,2A, A,3A).3A). The IC50 values for C9-BA-DANA in HPMECs (13.0
µM) were greater than its IC50 value in A549 cells (3.74 µM) or HLFs (4.82 µM), whereas its
IC50 values in A549 cells and HLFs were not significantly different. We asked whether
differential NEU1 and/or protective protein/cathepsin A (PPCA) expression might explain these
differences in total sialidase activity and IC50 values for C9-BA-DANA between these cell types.
First, a real-time RT-PCR approach was adopted to detect mRNA for NEU1 and PPCA in A549
cells, small airway epithelial cells (SAECs), HPMECs and HLFs (Figure (Figure4A).4A). Each
NEU1 or PPCA mRNA level was normalized to the 18 S rRNA level for the same sample. These
data indicate that at the mRNA level NEU1 expression was highest in HLFs, followed by
HPMECs, with the lowest in the two airway epithelia. PPCA mRNA expression was highest in

HPMECs, followed by HLFs and A549 cells, and lowest in SAECs. To establish relative NEU1
and PPCA protein expression in these cells, quantitative immunoblotting (Figure (Figure4B)4B)
was applied where the NEU1 or PPCA signal was normalized to both β-tubulin expression
(Figure (Figure4C)4C) and cell number (Figure (Figure4D).4D). When normalized to β-tubulin
or cell number, relative NEU1 protein expression in the four cell types was
HPMECs > SAECs > HLFs and A549 cells. When normalized to β-tubulin or cell number,
relative PPCA protein expression in the four cell types was A549 cells > SAECs and
HLFs > HMPECs. Finally, total sialidase activity normalized to mg protein (Figure
(Figure4E)4E) or cell number (Figure (Figure4F)4F) was highest in HPMECs, followed by
comparable levels in A549 cells and SAECs, and lowest in HLFs.

Fig. 4. Differential expression of NEU1 and PPCA in HAECs, HPMECs and HLFs. (A)
Quantitative RT-PCR analysis of NEU1 and PPCA mRNA levels in A549 cells, SAECs,
HPMECs and HLFs. Vertical bars represent mean NEU1 or PPCA mRNA levels normalized to
18 S rRNA mRNA levels. (B) Equivalent numbers of A549 cells (lanes 1, 5), SAECs (lanes 2,
6), HPMECs (lanes 3, 7) and HLFs (lanes 4, 8) were lysed and equivalent volumes were
processed for NEU1 (lanes 1–4) and PPCA (lanes 5–8) immunoblotting. To control for protein
loading and transfer, blots were stripped and reprobed for β-tubulin. IB, immunoblot; IB*,
immunoblot after stripping. Molecular weight in kDa is indicated on left (lanes 1–4) and right
(lanes 5–8). (C, D) Densitometric analyses of the blots in (B). Vertical bars represent mean
(±SE) NEU1 or PPCA signal normalized to β-tubulin signal in the same lane in the same stripped
and reprobed blot (C) or cell number (D) (n = 2/5). (E, F) A fixed amount of cellular protein
(A549 cells, 0.63 mg; SAECs, 0.78 mg; HPMECs, 0.71 mg; HLFs, 1.00 mg) (E) or a fixed
number of A549 cells, SAECs, HPMECs or HLFs (106 cells/reaction) (F) were assayed for
sialidase activity for 4-MU-NANA. Vertical bars represent mean (±SE) sialidase activity
corrected for activity in the absence of cells and expressed as arbitrary fluorescence units/mg
protein (E) or arbitrary fluorescence units/106 cells (F). In (E, F), the n for each experimental
group is indicated beneath each vertical bar. (G, H) Correlation of sialidase activity for 4-MUNANA in A549 cells (1), SAECs (2), HPMECs (3) and HLFs (4) versus (G) NEU1 protein
levels or (H) PPCA protein levels normalized to β-tubulin or cell number. Each result is
representative of three independent experiments.

The relative sialidase activity for the 4-MU-NANA substrate directly correlated with NEU1
protein expression levels normalized to β-tubulin (Figure (Figure4G).4G). Although the line of
correlation between sialidase activities to NEU1 expression normalized to cell number was
superimposable on that calculated for NEU1 expression normalized to β-tubulin, this correlation
did not achieve statistical significance (Figure (Figure4G).4G). In contrast to NEU1 levels
normalized to β-tubulin, relative sialidase activity did not increase with increasing relative PPCA
protein levels normalized to either β-tubulin or cell number (Figure (Figure4H).4H). To clarify
this issue, low NEU1-expressing, high PPCA-expressing A549 cells and high NEU1-expressing,
low PPCA-expressing HPMECs were infected with increasing multiplicities of infection (MOIs)
of Ad-NEU1 or Ad encoding for PPCA (Ad-PPCA), and the cells processed for NEU1 (Figure
(Figure5A,E)5A,E) or PPCA (Figure (Figure5C,G)5C,G) immunoblotting and sialidase activity
for the 4-MU-NANA substrate (Figure (Figure5B,D,F,H).5B,D,F,H). Infection of A549 cells and
HPMECs with increasing MOIs of Ad-NEU1 or Ad-PPCA dose-dependently increased NEU1
and PPCA protein expression, respectively (Figure (Figure5A,C,E,G).5A,C,E,G). Ectopic
overexpression of either NEU1 or PPCA in A549 cells increased sialidase activity by up to 1.7fold and >2.6-fold, respectively (Figure (Figure5B,D).5B,D). However, in high NEU1expressing, low PPCA-expressing HPMECs, overexpression of NEU1 was not associated with
increased sialidase activity (Figure (Figure5F),5F), whereas PPCA overexpression was (Figure
(Figure5H).5H). It is likely that NEU1 overexpression in HPMECs fails to increase sialidase
activity due to their low expression of PPCA, an established NEU1 chaperone that is required for
its catalytic activity. To establish the ability of C9-BA-DANA to inhibit sialidase activity
resulting from ectopic expression of either NEU1 or PPCA in A549 cells and HPMECs, these
same cells were infected with Ad-NEU1 or Ad-PPCA (MOI = 300), cultured for 48 h and

assayed for sialidase activity in the presence or absence of C9-BA-DANA (Figure (Figure5I).5I).
In NEU1-overexpressing A549 cells, C9-BA-DANA decreased sialidase activity by 88.8%, and
in PPCA-overexpressing A549 cells by 68.6%. In HPMECs, the inhibitor decreased sialidase
activity in PPCA-overexpressing cells by 64.1%. These combined data indicate that in either
A549 cells or HPMECs with enhanced sialidase activity provoked by either NEU1 or PPCA
overexpression, C9-BA-DANA dramatically reduces the activity.

Fig. 5. Increased sialidase activity in NEU1- or PPCA-overexpressing A549 cells and HPMECs
is inhibited by C9-BA-DANA. A549 cells (A–D) and HPMECs (E–H) were infected with
increasing MOIs of Ad-NEU1 (A, B, E, F) or Ad-PPCA (C, D, G, H). (A, C, E, G) After 48 h,
the cells were lysed and equal protein aliquots of lysates processed for NEU1 (A, E) or PPCA
(C, G) immunoblotting. To control for protein loading and transfer, the blots were stripped and
reprobed for β-tubulin. IB, immunoblot; IB*, immunoblot after stripping. Molecular weight in
kDa is indicated on left. (B, D, F, H) Sialidase activity for the 4-MU-NANA substrate was
assayed in A549 cells (B, D) and HPMECs (F, H) infected with increasing MOIs of either AdNEU1 (B, F) or Ad-PPCA (D, H). Vertical bars represent mean (±SE) sialidase activity
normalized to mg of cellular protein. *, increased sialidase activity in cells infected with AdNEU1 or Ad-PPCA versus uninfected cells at P < 0.05. (I) A549 cells and HPMECs infected

with Ad-NEU1 or Ad-PPCA (MOI = 300) were cultured for 48 h and assayed for sialidase
activity for the 4-MU-NANA substrate in the presence of 134 μM of C9-BA-DANA or medium
alone. Vertical bars represent mean (±SE) sialidase activity corrected for activity in the absence
of cells and normalized to mg of cellular protein. *, increased sialidase activity in Ad-NEU1infected or Ad-PPCA-infected cells versus uninfected cells at P < 0.05. **, decreased sialidase
activity in C9-BA-DANA-treated cells versus untreated cells at P < 0.05. The n for each
experimental group is indicated in each panel. Each result is representative of three independent
experiments.

C9-BA-DANA displays less inhibitory activity for neuraminidases expressed by
Arthrobacter ureafaciens, Clostridium perfringens and Vibrio cholerae
We reported that C9-BA-DANA selectively inhibited human NEU1 (IC50 = 10 µM) relative to
human NEU2, -3 and -4 (IC50 > 1000 µM) (Magesh et al. 2008). Among the four known human
NEUs, NEU1 shares the least homology with the other three (Monti et al. 2002, 2010; Miyagi
and Yamaguchi 2012). In fact, NEU1 might be more closely related to some prokaryotic
neuraminidases than the other human NEUs (Kiyohara et al. 2011). Furthermore, numerous
microbes that express their own neuraminidases are known to colonize, or in some instances,
infect humans (Kim et al. 2011; Lewis and Lewis 2012). To establish whether C9-BA-DANA
might inhibit bacterial neuraminidases, we established the IC50 for C9-BA-DANA for each of
three bacterial neuraminidases selected for their phylogenetic relatedness to human NEU1
(Kiyohara et al. 2011) (Figure (Figure6).6). We found the IC50 for C9-BA-DANA to be 890 µM
for Arthrobacter ureafaciens neuraminidase (Figure (Figure6A),6A), and >1000 µM for both
Clostridium perfringens neuraminidase NanI (Figure (Figure6B)6B) and Vibrio cholerae
neuraminidase (Figure (Figure6C).6C). These combined data indicate that C9-BA-DANA is
selective for human NEU1 not only relative to the other human NEUs (Magesh et al. 2008), but
also relative to the bacterial neuraminidases studied here.

Fig. 6. C9-BA-DANA exerts far less inhibitory activity for prokaryotic neuraminidases. Fixed
concentrations of the neuraminidases expressed by (A) A. ureafaciens (7.5 ng/mL), (B) C.
perfringens (NanI) (40 ng/mL) and (C) V. cholerae (625 ng/mL) were each assayed for sialidase
activity for 4-MU-NANA in the presence of increasing concentrations of C9-BA-DANA. The
concentration chosen for each bacterial neuraminidase generated catalytic activity for the 4-MUNANA substrate comparable to that seen with the simultaneous positive control using A549 cells
at 106 cells/reaction. Each symbol represents mean (±SE) neuraminidase activity corrected for
activity in the absence of bacterial neuramindase and expressed as arbitrary fluorescence
units/mg protein (n = 2/3). The broken line in each panel represents the linear trendline with the
corresponding equation and correlation coefficient (R2) value determined using Microsoft Excel.
Insert in (B) represents the silver-stained gel of resolved C. perfringens neuraminidase
preparation. Molecular weight in kDa indicated on left. Arrow on right indicates NanI band of
interest. Each result is representative of two or three independent experiments.

Predicted steric hindrances to C9-BA-DANA in bacterial neuraminidases
To better understand why C9-BA-DANA is selective for NEU1, not only among the human
sialidases (Magesh et al. 2008), but also relative to the bacterial neuraminidases studied here, we
compared the X-ray crystal structures of C. perfringens NanI (Protein Database ID 2VK6) and
the V. cholerae neuraminidase (Protein Database ID 1W0O) to models of the neuraminidase of
A. ureafaciens and NEU1 bound with C9-BA-DANA, for which no high-resolution structures are
available. Importantly, DANA, upon which C9-BA-DANA is based, is able to bind and inhibit
all of the neuraminidases/sialidases used in this study (Meindi and Tuppy 1969; Burmeister et al.
1993). After superimposition of the X-ray crystal structures and models, we examined the results

for any causes of gross steric or electrostatic incompatibility between C9-BA-DANA and the
bacterial neuraminidases. We found that universally, the polypeptide loop between the seventh
and eighth strands of the β-propeller fold (the β7–β8 loop) is substantially longer in the bacterial
neuraminidases compared with the β7–β8 loop of human NEU1 (Figure (Figure7A–C).7A–C).
Modeling studies predict that the longer β7–β8 loops of the bacterial neuraminidases may
interfere with C9-BA-DANA accessibility to their catalytic domains. These steric clashes
between amino acid side-chains extending from these loops and the n-butyl group linked to the
C9 position of the inhibitor are absent in the NEU1-C9-BA-DANA model. Furthermore, amino
acid sequence alignments between human NEU1 and human NEU2, -3 and -4 indicate that like
the bacterial neuraminidases the β7–β8 loops in NEU2, -3 and -4 are longer than the β7–β8 loop
in NEU1 (Figure (Figure7D)7D) (Magesh et al. 2006). The presence of an extended β7–β8 loop
in NEU2, -3 and -4 might explain their relative resistance to inhibition by C9-BA-DANA, while
absence of the n-butyl group in DANA might account for its ability to inhibit all four human
sialidases. However, the ability of DANA molecules with phenyl-containing substituents at C9 to
inhibit NEU2 and NEU3 argues that accommodation of larger substituents at C9 is possible for
sialidases with longer β7–β8 loops under some circumstances, suggesting that favorable
interactions with phenyl rings may drive loop remodeling (Magesh et al. 2008; Zhang et al.
2013). Similarly, a DANA-derivative with a large polar C9-substituent was found to be a highly
potent inhibitor of NEU4, suggesting that electrostatic interactions with a methanol moiety at the
tip of a triazol ring were similarly stabilizing (Albohy et al. 2013). The ability of NEU1 to
accommodate a variety of hydrophobic moieties at C9, unlike NEU2, -3 and -4 (and the bacterial
neuraminidases studied here) may indicate that these substituents prevent the β7–β8 loops of
NEU2, -3 and -4 from adopting their native structures without stabilizing any alternative
conformations. As previously reported (Magesh et al. 2008), other potential sites in NEU2, -3
and -4 for steric hindrance with C9-BA-DANA were identified, including a shared Tyr residue
(Y181 in NEU2 and -3, Y179 in NEU4) outside of the β7–β8 loop.

Fig. 7. Predicted steric hindrance to C9-BA-DANA binding to bacterial neuraminidases.
Structural superimposition of the C9-BA-DANA–NEU1 complex (gray) with (A) A. ureafaciens
neuraminidase (orange), (B) C. perfringens NanI (blue) and (C) V. cholerae neuraminidase
(green). Only the β7–β8 loops of the bacterial neuraminidases are depicted. V. cholerae
(National Center for Biotechnology Information, Protein Database ID #1W0O) and C.
perfringens (National Center for Biotechnology Information, Protein Database ID #2VK6)
neuraminidase structures are X-ray crystal structures. A. ureafaciens neuraminidase and NEU1
structures are based on homology modeling with the NEU2 X-ray crystal structure. (D) Amino
acid sequence alignments of the β7–β8 loop from human NEU1, -2, -3 and -4 and the three
bacterial neuraminidases are shown. This figure is available in black and white in print and in
color at Glycobiology online.

C9-BA-DANA inhibits flagellin-induced increases in mouse lung sialidase
activity in vivo
In wild type mice, the highest levels of sialidase activity were detected in kidney tissue, and
when compared with the kidney tissues of NEU1-null mice, sialidase activity could be almost
exclusively ascribed to NEU1 (de Geest et al. 2002). First, to test whether C9-BA-DANA could
inhibit NEU1 catalytic activity in vivo, total sialidase activities for the 4-MU-NANA substrate in

kidney tissues obtained from mice preadministered with the inhibitor or PBS vehicle alone were
assayed (Figure (Figure8A).8A). Prior administration of C9-BA-DANA inhibited renal sialidase
activity by 90.6% compared with the PBS controls. Preadministration of the broad spectrum
sialidase inhibitor, DANA, diminished renal sialidase activity to a comparable degree (Figure
(Figure88A).

Fig. 8. C9-BA-DANA prevents flagellin-induced increases in mouse lung sialidase activities in
vivo. (A) Mice were injected intraperitoneally with 15 μg/kg of C9-BA-DANA (n = 3) or DANA
(n = 3), or PBS vehicle alone (n = 3). After 24 h, mice were euthanized and kidneys were
harvested, weighed and homogenized. Kidney homogenates were processed for assays for total
protein levels and total sialidase activity for the 4-MU-NANA substrate. Vertical bars represent
mean (±SE) total kidney sialidase activity in arbitrary fluorescence units/mg protein. *,
decreased sialidase activity in kidneys of C9-BA-DANA- or DANA-treated versus PBS-infused
mice at P < 0.05. (B) Mice were injected intraperitoneally with 15 μg/kg of C9-BA-DANA
(n = 13) or DANA (n = 14) or PBS vehicle alone (n = 29). After 24 h, mice pretreated
intraperitoneally with C9-BA-DANA were challenged intranasally with 100 ng/mouse of Paderived flagellin (n = 10) or PBS (n = 3), mice pretreated with DANA were challenged with
flagellin (n = 7) or PBS (n = 7), and mice pretreated with PBS were challenged with flagellin
(n = 13) or PBS (n = 16). After 4 h, mice were euthanized and lungs were harvested, weighed
and homogenized. Lung homogenates were processed for assays for total protein levels and total
sialidase activity for the 4-MU-NANA substrate. Vertical bars represent mean (±SE) lung
sialidase activity corrected for activity in the absence of a tissue sample and expressed as
arbitrary fluorescence units/mg protein. *, decreased sialidase activity in C9-BA-DANA- or
DANA-treated lung tissue versus PBS controls at P < 0.05. **, increased sialidase activity in
flagellin-stimulated lung tissue versus PBS control at P < 0.05. Each result is representative of
three independent experiments.

C9-BA-DANA dose-dependently inhibited sialidase activity in in vitro cultures of HAECs
(Figure (Figure1A),1A), HPMECs (Figure (Figure2A)2A) and HLFs (Figure (Figure3A).3A).
Furthermore, stimulation of HAECs with Pa flagellin increased NEU1-mediated MUC1-ED
desialylation, adhesiveness for Pa and shedding, all of which were inhibited by C9-BA-DANA
(Figure (Figure1C–F).1C–F). We asked whether C9-BA-DANA might inhibit total lung sialidase
activity in an in vivo setting. In the lungs of PBS-administered control mice, basal levels of total
sialidase activity for the 4-MU-NANA substrate were detected (Figure (Figure8B).8B).
Administration of C9-BA-DANA 24 h prior to harvesting lungs reduced baseline sialidase
activity by 59.7%. In flagellin-challenged mice, total lung sialidase activity increased by 46.7%
compared to the PBS-administered controls in the absence of C9-BA-DANA. Preadministration
of C9-BA-DANA completely prevented the flagellin-induced increase in lung sialidase activity.
Finally, preadministration of DANA also inhibited lung sialidase activity in the absence or
presence of the flagellin stimulus, both of which were equivalent to the inhibition seen by C9BA-DANA. These findings indicate that the ability of C9-BA-DANA to inhibit sialidase activity
in HAECs (Figure (Figure1A),1A), HPMECs (Figure (Figure2A)2A) and HLFs (Figure
(Figure3A)3A) can be extended to an intact in vivo model. Sialidases other than NEU1 are
known to be expressed in lung tissue (Bonten et al. 1996; Igdoura et al. 1998; Cross et al. 2012;
Lillehoj et al. 2012, 2015). However, the decreases in flagellin-provoked lung sialidase activities
in response to C9-BA-DANA and the more broad spectrum DANA were comparable (Figure
(Figure8B),8B), not supporting the involvement of sialidases other than NEU1. It is still
conceivable, however, that one or more of these other sialidases might explain the C9-BADANA-unresponsive lung sialidase activity.

Discussion
In the current studies, C9-BA-DANA reduced total sialidase activity in lung epithelia (Figure
(Figure1A),1A), endothelia (Figure (Figure2A)2A) and fibroblasts (Figure (Figure3A).3A). In
HAECs, at the mRNA level, NEU1 is expressed at levels >7500-fold greater than NEU2, >500fold greater than NEU3 and >4000-fold greater than NEU4 (Lillehoj et al. 2012). In HPMECs,
NEU1 is expressed at levels >8700-fold greater than NEU2, >500-fold greater than NEU3 and
>5000-fold greater than NEU4 (Cross et al. 2012). Prior siRNA-induced silencing of NEU1 in
both lung epithelia and endothelia reduced total sialidase activity for the 4-MU-NANA substrate
by >70% (Cross et al. 2012; Lillehoj et al. 2012). The second most abundant sialidase in these
cells, NEU3, may be less active for the 4-MU-NANA substrate (Wada et al. 1999). However, a
more recent report indicates otherwise (Smutova et al. 2014). These combined data indicate that
C9-BA-DANA can inhibit total sialidase activity in HAECs, HPMECs and HLFs, and that
almost all of this sialidase activity can be ascribed to NEU1.
Of the four known mammalian sialidases, NEU1 is the most abundant and widely distributed
(Monti et al. 2002, 2010; Miyagi and Yamaguchi 2012). NEU1, like many other gene products,
is differentially expressed in various organs and tissues (Bonten et al. 1996; Igdoura et al. 1998).
The human NEU1 transcript appears to be most abundant in pancreas, followed in decreasing

order by skeletal muscle, kidney, heart, placenta, liver, lung and at very low levels, brain (Bonten
et al. 1996). In the mouse, the highest levels of NEU1 mRNA expression were found in kidney
and epididymis, with moderate levels in the brain and spinal cord, and lower levels in adrenal,
liver, lung, spleen and heart (Igdoura et al. 1998). Although NEU1 gene expression in the lung is
relatively modest, it is absolutely essential to normal lung development (Starcher et al. 2008).
NEU1-null mice exhibit impaired septation and alveolarization resulting in enlarged air spaces.
Just as NEU1 is differentially expressed throughout human tissues (Bonten et al. 1996), we now
have demonstrated that its expression within the lung itself is heterogeneous for distinct cell
types.
The IC50 in HPMECs (13.0 µM) was 3.5-fold higher than that established for A549 cells (3.74
µM) and 2.7-fold higher than that found for HLFs (4.82 µM). Several properties might explain
the requirement for higher concentrations of C9-BA-DANA in HPMECs to provide equivalent
inhibition to that seen in the other two cell types. Total baseline sialidase activity in resting,
unstimulated HMPECs (Figure (Figure2A)2A) was >1.7-fold higher than that detected in an
equivalent number of resting, unstimulated A549 cells (Figure (Figure1A)1A) and >3.6-fold
higher than that found in HLFs (Figure (Figure3A).3A). We asked whether differential
expression of NEU1 and/or its transport/chaperone protein, PPCA, might explain the higher
sialidase activity in HPMECs. We found that NEU1 protein expression normalized to β-tubulin
or cell number was >1.9-fold higher in HPMECs compared to its expression in A549 cells, >1.2fold higher compared to its expression in SAECs and >1.7-fold higher compared to its
expression in HLFs (Figure (Figure4C,D).4C,D). In contrast, normalized PPCA protein
expression was lowest in HPMECs and highest in A549 cells (Figure (Figure4C,D).4C,D).
Among the four cell types analyzed, increasing NEU1 protein levels significantly correlated with
increasing sialidase activity for the 4-MU-NANA substrate (Figure (Figure4G).4G).
Unexpectedly, increasing PPCA protein levels did not correlate with sialidase activity (Figure
(Figure4H).4H). To further clarify the contributions of NEU1 and PPCA to cellular sialidase
activity, NEU1 and PPCA each were dose-dependently overexpressed in low NEU1-expressing,
high PPCA-expressing A549 cells and high NEU1-expressing, low PPCA-expressing HPMECs
(Figure (Figure5).5). In A549 cells, overexpression of either NEU1 or PPCA increased sialidase
activity (Figure (Figure5B,D),5B,D), whereas in HPMECs, PPCA overexpression increased
sialidase activity (Figure (Figure5H)5H) while NEU1 overexpression did not (Figure
(Figure5F).5F). These combined data indicate that (1) NEU1 and PPCA protein expression and
sialidase activity differ in distinct cell types and tissues, (2) NEU1 protein expression correlates
with sialidase activity, (3) endogenous PPCA expression can be a limiting factor for NEU1mediated sialidase activity and (4) differential NEU1 and/or PPCA expression may dictate
cellular responsiveness to C9-BA-DANA.
The experimental conditions required for each of the essays described in this study might
contribute to the inconsistent effects of C9-BA-DANA. First, the 4-MU-NANA assay for
sialidase catalytic activity (Figures (Figures1A,1A, A,2A,2A, A,3A,3A, A,4E,F,4E,F,
E,F,5B,D,F,H,I)5B,D,F,H,I) involves treatment of cells with the detergent, Triton X-100, which
permeabilizes the plasma membrane likely permitting increased entry into and/or exit from cells.
The PNA lectin blotting (Figure (Figure1C,D)1C,D) and adhesion assays (Figure (Figure1E)1E)
are performed within 30 min of the flagellin stimulus, whereas the MUC1-ED shedding
experiments (Figure (Figure1F)1F) are carried out after 24 h. The stability of C9-BA-DANA in

aqueous culture medium at 37°C over time has not been defined. MUC1-ED exhibits a β-turn
helix resulting from its high proline content (Fontenot et al. 1995). This extended rod-like
conformation allows MUC1 to protrude higher above the airway epithelial surface than most
membrane-associated proteins. MUC1-ED desialylation and altered bacterial adhesion likely
occur at the outermost position of glycan chains where the terminal sialic acid residues are
located (Lillehoj et al. 2013). In the PNA lectin blotting studies which assayed MUC1-ED
desialylation, C9-BA-DANA at 10 µM inhibited desialylation by 42.0%, and at 100 µM, by
78.7% (Figure (Figure1C,D).1C,D). In the Pa adhesion assays, C9-BA-DANA at 10 µM
inhibited adhesion by 43.1%, and at 100 µM, by 67.5% (Figure (Figure1E).1E). In contrast, the
protease recognition site where proteolytic cleavage and shedding of the MUC1-ED occur is
located at a Gly-Ser peptide bond located 58 amino acids upstream of the transmembrane domain
within the extracellular, juxtamembranous region (Parry et al. 2001). In the MUC1-ED shedding
assays, C9-BA-DANA at 10 µM inhibited shedding only by 23.8%, and at 100 µM, only by
46.7% (Figure (Figure1F).1F). Whether such differences in the site of NEU1 activity and sialic
acid removal influences, the ability of C9-BA-DANA to interact with NEU1 to inhibit its
catalytic activity is unclear. Other possible explanations might include differences in intracellular
and/or cell surface pH, and/or distinct cellular volumes and/or plasma membrane/glycocalyx
properties that dictate C9-BA-DANA entry into the intracellular compartment and accessibility
to the NEU1 sialidase. Unlike the experiments performed with HAECs (Figure (Figure1C–
F),1C–F), the sialidase activity in HPMECs was comprised of both endogeneous NEU1 and
ectopically expressed NEU1 through Ad-NEU1 infection (Figure (Figure2B–E).2B–E). C9-BADANA dramatically reduced sialidase activity in NEU1-overexpressing cells (Figure
(Figure5I).5I). Whether endogenous and ectopically expressed NEU1 are equally catalytically
active on a molar basis and/or equally susceptible to the inhibitory activity of C9-BA-DANA
have not been tested.
The selectivity of C9-BA-DANA for human NEU1, relative to bacterial neuraminidases, may
have implications for its potential therapeutic application. A number of commensal bacteria
express neuraminidases that can facilitate their acquisition of carbohydrate nutrients and regulate
their physical presentation to host tissues and recognition by the immune system (Kim et al.
2011; Lewis and Lewis 2012). Since any intervention that disrupts bacterial neuraminidases
might exert an unpredictable impact on host–microbe and microbe–microbe interactions, a more
selective approach is theoretically preferable.
NEU1 reportedly influences multiple biological processes. Evidence exists to support a role for
NEU1 in aspects of microbial pathogenesis, innate immunity and the sepsis syndrome (Cross et
al. 2003; Grewal et al. 2008; Amith et al. 2009, 2010; Seyrantepe et al. 2010; Abdulkhalek et al.
2011, 2012; Feng et al. 2012, 2013; Lillehoj et al. 2012, 2015; Abdulkhalek and Szewczuk
2013). NEU1 participates in TLR activation (Amith et al. 2009, 2010; Abdulkhalek et al.
2011, 2012; Feng et al. 2012; Abdulkhalek and Szewczuk 2013), including TLR4 responsiveness
to its ligand, bacterial lipopolysaccharide (LPS) or endotoxin (Amith et al. 2010; Abdulkhalek et
al. 2011; Feng et al. 2012), and influences macrophage phagocytosis (Seyrantepe et al. 2010). Pa
hijacks human NEU1 to desialylate its receptor, the MUC1-ED, which in turn, increases bacterial
adhesion to and invasion of the airway epithelium (Lillehoj et al. 2012, 2015). Sialidase activity
regulates complement-mediated pulmonary leukostasis and transendothelial recruitment of
granulocytes into the bronchoalveolar compartment (Cross et al. 2003), and finally, the

development of endotoxin-induced acute lung injury (Feng et al. 2013). In one study, the
coagulopathy associated with Streptococcus pneumoniae sepsis was ascribed to bacterial
neuraminidase (Grewal et al. 2008). The role(s) of one or more human sialidase(s) was not
considered. Sialic acid and its metabolism also reportedly contribute to the atherogenic process
(Tertov et al. 1998; Golovanova et al. 2002; Mochizuki et al. 2002; Cuniberti et al. 2005; Gopaul
and Crook 2006; Gayral et al. 2014). Serum sialic acid is a predictive biomarker for coronary
artery disease (Gopaul and Crook 2006) and desialylation of low-density lipoproteins (Tertov et
al. 1998) and the arterial surface (Cuniberti et al. 2005) facilitates neointimal development and
atherogenesis. Sialidase activity is elevated in the atherosclerotic aortic intima (Golovanova et al.
2002) and NEU1 is essential to elastin receptor signaling (Hinek et al. 2006, 2008; Duca et al.
2007; Starcher et al. 2008), which in turn, increases arterial smooth muscle proliferation and
enhances atheroma plaque size progression (Mochizuki et al. 2002; Gayral et al. 2014). Finally,
NEU1 overexpression impairs the endothelial migratory response to injury (Figure
(Figure2C,D)2C,D) (Cross et al. 2012; Lee et al. 2014). More recently, we reported that NEU1
expression is upregulated in the lungs of IPF patients (Luzina et al. 2016). It is conceivable that a
NEU1-selective sialidase inhibitor such as C9-BA-DANA might offer a novel therapeutic
intervention for sepsis, atherosclerotic arterial disease, IPF and/or other human disease states.

Materials and methods
Reagents
Precast SDS-polyacrylamide gels were from Novex (San Diego, CA). Polyvinylidene fluoride
(PVDF) membrane was from Millipore (Bedford, MA). Enhanced chemiluminescence reagents
and prestained protein molecular weight markers were from BioRad (Hercules, CA). Mouse
antihuman NEU1 monoclonal antibody was from Origene (Rockville, MD). Rabbit anti-PPCA
antibody was from Abcam (Cambridge, MA). Mouse anti-Physarum β-tubulin antibody was
from Boehringer-Mannheim (Indianapolis, IN). Horseradish peroxidase-conjugated goat
antirabbit and goat-antimouse secondary antibodies were from Cell Signaling Technology
(Danvers, MA). PNA and PNA-agarose were from Vector Laboratories (Burlingame, CA).
DANA was from Calbiochem (San Diego, CA). C9-BA-DANA was prepared as previously
described (Magesh et al. 2008).

Human lung cell cultures
A549 cells are an alveolar type II cell line derived from a lung adenocarcinoma (American Type
Culture Collection, Manassas, VA). A549 cells were cultured in Dulbecco's modified Eagle's
medium (DMEM) containing 10% fetal bovine serum (Hyclone Laboratories, Logan, UT), 50
units/mL penicillin and 50 µg/mL streptomycin, as described (Lillehoj et al. 2012). Human
primary SAECs isolated from the distal portion of the bronchioles (PromoCell, Heidelberg,
Germany) were cultured as described (Lillehoj et al. 2012, 2015). SAECs were studied in
passages 2–4. HPMECs (PromoCell) were cultured in endothelial cell growth medium (MV-2,
PromoCell) containing growth medium supplement mix (PromoCell) as described (Cross et al.
2012; Lee et al. 2014). HPMECs were studied in passages 4–7. Primary normal adult HLFs

(Lonza, Rockland, ME) were cultured in DMEM supplemented with 2.0 mM glutamine, 2.0 mM
sodium pyruvate, 50 mg/L gentamicin and 10% fetal bovine serum, as described (Nacu et al.
2008). All HLF cultures were passaged by trypsinization and used for experiments in passages
3−7.

Fluorometric assay for sialidase activity
A549 cells, HPMECs and HLFs (106 cells/reaction) were suspended in 200 µL of 500 mM
sodium acetate, pH 4.4 containing 0.1% Triton X-100 and protease inhibitor mixture (Roche
Applied Science, Branford, CT) in the presence of increasing concentrations of C9-BA-DANA.
The cell-containing mixtures were then incubated for 1 h at 37°C with 25 µL of 2.0 mM 4-MUNANA, mixing the tubes every 15 min. The sialidase reaction was terminated by addition of 1.0
mL of 133 mM glycine, pH 10.3, 60 mM NaCl and 0.083 M Na2CO3, after which fluorescence
intensity was measured with a fluorometer (excitation at 355 nm; emission at 460 nm), as
described (Cross et al. 2012; Lillehoj et al. 2012). Half maximal inhibitory concentration (IC50)
values of C9-BA-DANA were calculated using the ED50V10 Microsoft Excel add-in
(http://www.sciencegateway.org/protocols/cellbio/drug/hcic50.htm) with background corrected
fluorescence values and log10-transformed C9-BA-DANA concentrations. The same 4-MUNANA fluorogenic substrate was used to establish the IC50 values of C9-BA-DANA for
neuraminidases expressed by A. ureafaciens (Roche), C. perfringens (Sigma, St. Louis, MO) and
V. cholerae (Roche, Indianapolis, IN). C. perfringens is known to express three distinct
neuraminidases, NanH (42.8 kDa), NanI (77.4 kDa), and NanJ (~140 kDa) (Newstead et al.
2008). Since the commercial source for the clostridial neuraminidase could not specify, which
neuraminidase(s) was contained in their product, the preparation was resolved by SDS-PAGE
and the gel processed for silver staining according to the manufacturer's protocol (Life
Technologies, Carlsbad, CA). The resolved preparation contained a single protein band with a
molecular weight of ~77.0 kDa, compatible with NanI. To control for interassay variability, a
simultaneous positive control using A549 cells at 106 cells/reaction was included with each
assay. To address the dissimilar purities and specific activities for the bacterial neuraminidases, a
concentration range for each enzyme was tested for catalytic activity for the 4-MU-NANA
substrate, and a concentration that generated catalytic activity comparable to that seen with the
A549 cell control was chosen for IC50 studies for the C9-BA-DANA inhibitor. The concentration
chosen was 7.5 ng/mL for A. ureafaciens neuraminidase, 40 ng/mL for C. perfringens NanI and
625 ng/mL for V. cholerae neuraminidase.

Pa culture and flagellin purification
Pa strain PAO1 was cultured overnight in Luria-Bertani broth, washed twice with PBS,
resuspended in PBS containing 2.0 mg/mL glucose and quantified spectrophotometrically at
A600, as described (Lillehoj et al. 2012, 2015). An overnight culture of Pa was centrifuged at
5000 × g for 30 min, resuspended in Krebs-Ringer buffer, and incubated for 1 h at 37°C, as
described (Lillehoj et al. 2012, 2015). The bacteria were removed by centrifugation, and the
supernatant was filtered through a 0.22-µm-pore membrane (Millipore) and boiled for 20 min.
The supernatant was concentrated by ultrafiltration (Millipore; 30-kDa cutoff), adjusted to pH
6.0, and incubated for 30 min at room temperature with 0.5 mL of Macro-Prep High S support,
pH 6.0. The matrix was removed by centrifugation, and the flagellin-containing supernatant was

applied to a 2.0-mL Macro-Prep High Q column. The column was washed with 20 mM TrisHCl, pH 8.0 and flagellin was eluted with 100 mL of a linear 0.0–1.0 M NaCl gradient. Fractions
(1.0 mL) were collected and analyzed for the 50-kDa flagellin protein band by SDS-PAGE.
Immunoblots were probed with rabbit anti-Pa flagellin antibody (provided by Dr. Dan Wozniak,
Wake Forest University, Winston-Salem, NC) and with rabbit antipilin antibody (provided by
Dr. Randy Irvin, University of Alberta, Alberta, Canada) to confirm the absence of pilin
contamination. Flagellin-containing fractions were preadsorbed with polymyxin B-agarose to
remove bacterial LPS, after which less than 0.1 LPS units/µg of protein was detected by the
Limulus amebocyte lysate assay.

PNA lectin blotting of desialylated MUC1-ED
A549 cells were incubated for 30 min at 37°C with 10 ng/mL flagellin or medium alone,
solubilized with lysis buffer as described (Lillehoj et al. 2012, 2015), and 1.0 mg aliquots were
incubated with PNA immobilized on Sepharose beads (Vector Labs, Burlingame, CA) to
selectively enrich for PNA-binding proteins. The PNA-bound proteins were resolved by SDSPAGE, transferred to PVDF, and the blots incubated with mouse antihuman MUC1-ED antibody
(clone GP1.4, Biomedia, Foster City, CA), as described (Lillehoj et al. 2012, 2015). Asialofetuin
(1.0 µg) was used as a positive control for PNA-binding proteins, whereas fetuin (1.0 µg) was
used as a negative control.

Pa adhesion to HAECs
A549 cells were incubated for 30 min at 37°C with 10 ng/mL of Pa-derived flagellin or medium
alone, after which they were washed twice with PBS, fixed for 10 min with 2.5% glutaraldehyde
in PBS at room temperature, and washed three times with PBS as described (Lillehoj et al. 2012,
2015). Fixed cells (2.0 × 105/well) in 24-well plates were incubated with 2.0 × 107 colonyforming units (CFU)/well of PAO1 in 0.5 mL for 40 min at 37°C and washed three times with
PBS. Bound bacteria were released with 0.05% trypsin, and bound CFUs quantified as described
(Lillehoj et al. 2012, 2015).

ELISA for MUC1-ED
A549 cell-conditioned culture media were centrifuged at 10,000 × g for 10 min at 4°C, added in
triplicate to 96-well ELISA plates (MaxiSorb; Nalge Nunc, Rochester, NY) and incubated
overnight at 4°C. Wells were blocked for 1 h at room temperature with PBS, pH 7.0, containing
10 mg/mL bovine serum albumin and 50 mg/mL sucrose, and washed with PBS containing
0.05% Tween-20 (PBS-T). The samples were reacted for 2 h at room temperature with 200
µg/mL of primary MUC1-ED antibody, washed with PBS-T, reacted for 2 h at room temperature
with 200 µg/mL of peroxidase-conjugated goat-antimouse IgG secondary antibody (KPL,
Gaithersburg, MD) and washed with PBS-T. Bound antibodies were detected with
tetramethylbenzidine substrate (SureBlue, KPL). The substrate reaction was stopped with 1 N
HCl, and A450 measured using a microplate spectrophotometer (Dexall, Gaithersburg, MD), as
described (Lillehoj et al. 2015).

HPMEC migration in a wounding assay
HPMECs were seeded at 2.0 × 105 cells/well in the wells of a 24-well plate (Corning, Corning,
NY), and after 3 h, infected with recombinant Ad-NEU1 or Ad-GFP (MOI = 100), as described
(Lee et al. 2014). The HPMECs were cultured for 48 h to confluence. Using a sterile 200 µL
pipette tip, a single wound was made across the diameter of each monolayer, after which the cell
debris was removed by washing with HEPES, as described (Cross et al. 2012; Lee et al. 2014).
The wounded monolayers were then incubated for 24 h in the absence or presence of 134 µM of
C9-BA-DANA. At 24 h, photomicrographs of each well were taken with a Nikon inverted
microscope. HPMEC area was calculated using ImageJ software for comparison with that
observed in the same wounded monolayer at 0 h, as a measure of migration into the wound.

In vitro HPMEC capillary-like tube formation
Each well of a 96-well plate was coated with 50 µL of Matrigel (10 mg/mL; BD Biosciences,
Sparks, MD), as described with modifications (Lee et al. 2014). Briefly, Matrigel was allowed to
polymerize for 1 h at room temperature in each of the wells, followed by 1 h at 37°C in a
humidified atmosphere at 5% CO2. HPMECs infected with Ad-GFP or Ad-NEU1 (MOI = 100)
were seeded at 7.5 × 103 cells/well onto the Matrigel-coated wells, in the presence 134 µM of
C9-BA-DANA or medium alone. At 6 h, tubular structures were photographed through a Nikon
inverted microscope, and segments of capillary-like tubes per high power field (HPF) were
counted.

Quantitative RT-PCR for human NEU1 and PPCA transcripts
Total cellular RNA was extracted from A549 cells, SAECs, HPMECs and HLFs, as described
(Cross et al. 2012; Lillehoj et al. 2012). RNA purity was established with the 260/280 nm
absorption ratio (>1.90). Total RNA (1.0 µg) was treated with DNase I (Invitrogen, Carlsbad,
CA) for 15 min and reverse transcribed using avian myelobastosis virus reverse transcriptase and
poly(T) primer (Promega, Madison, WI). The resulting cDNA was quantified by PCR using
SYBR Green PCR Master Mix and an ABI Prism 7900HT cycler. Primers for detection of
human NEU1 and PPCA mRNAs were designed using Primer Express 2.0 (Applied Biosystems,
Foster City, CA), as described (Cross et al. 2012; Lillehoj et al. 2012). Relative NEU1 and PPCA
gene expression was calculated using the 2−ΔΔCt method where NEU1 and PPCA transcripts were
normalized to the levels of 18 S rRNA transcripts as the internal control, as described (Cross et
al. 2012; Lillehoj et al. 2012).

Quantitative immunoblotting for human NEU1 and PPCA proteins
To establish relative NEU1 and PPCA protein expression in various human lung cells, equivalent
numbers of A549 cells, SAECs, HPMECs and HLFs were lysed and equivalent lysate volumes
were processed for NEU1 and PPCA immunoblotting, as described (Cross et al. 2012; Lillehoj et
al. 2012; Lee et al. 2014). To control for protein loading and transfer for the NEU1 and PPCA
immunoblots, the blots were stripped and reprobed for β-tubulin. NEU1 and PPCA signals were
normalized to both cell number and β-tubulin signal in the same lane in the same stripped and
reprobed blot.

Adenoviral constructs encoding for PPCA
A plasmid encoding for human PPCA (pSCTop-PPCA) was generously provided by Drs E.
Bonten and A. d'Azzo (St. Jude Children's Research Hospital, Memphis, TN). A
recombinant Ad-PPCA was generated using the AdEasy Ad Vector System (Stratagene, La Jolla,
CA) as described for other gene products (Cross et al. 2012; Lillehoj et al. 2012). Briefly, the
pSCTop-PPCA was digested with SalI and NotI and subcloned into a shuttle vector (pShuttle
CMV, Stratagene) using the same restriction enzymes followed by ligation. The shuttle plasmid
was linearized through PmeI digestion and, with the Ad backbone plasmid (pAdEasy-1,
Qbiogene, Carlsbad, CA), was used to co-transform electrocompetent Escherichia coli BJ5183
cells to produce the recombinant plasmid, Ad-PPCA. Recombinants were selected for kanamycin
resistance and screened for recombination by Pac1 restriction enzyme analysis and agarose gel
electrophoresis. The correct recombinant plasmids were used to transform DH5α cells, and
bacterial lysates were passed through Maxiprep columns (Qiagen, Valencia, CA) for purification.
Ad-PPCA was linearized with PacI digestion and transfected, in the presence of Lipofectamine
(Invitrogen), into AD-293 cells. After 7–10 d, cells were scraped off flasks with a rubber
policeman and subjected to three freeze-thaw cycles, and virus was harvested in the supernatants
for presentation to fresh AD-293 cells and titration in a plaque-forming assay. A549 cells and
HPMECs were transiently infected with packaged Ad-PPCA at increasing MOIs and after 48 h
were lysed, and the lysates processed for PPCA immunoblotting and the fluorometric assay for
sialidase activity.

Cell viability
A549 cells, HPMECs and HLFs were seeded into the wells of 48-well plates and cultured to 80%
confluence. The cells were cultured for 20 h in the presence of 100 µM of C9-BA-DANA or
medium alone, after which 250 ng/mL of 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium
bromide (MTT) was added for an additional 4 h incubation. The medium was aspirated and 100
µL of DMSO added and mixed by pipette. After 10 min, each well was again mixed and A490
measured.

Homology modeling of the C9-BA-DANA–NEU1 complex with bacterial
neruaminidases
Homology models of human NEU1 and A. ureafaciens neuramidase were constructed by
multitemplate modeling using Phyre2 protein fold recognition software (Kelley et al. 2015)
based on the X-ray diffraction crystal structure of NEU2 (National Center for Biotechnology
Information, Bethesda, MD, Protein Database ID #1VCU) (Chavas et al. 2005). C9-BA-DANA
was docked onto the NEU1 structure using AutoDock Vina software (Trott and Olson 2010),
resulting in a model similar to that previously described by Magesh et al. (2006, 2008). X-ray
structures for V. cholerae (Protein Database ID #1W0O) (Moustafo et al. 2004) and C.
perfringens NanI (Protein Database ID #2VK6) (Newstead et al. 2008) neuraminidases and the
model of A. ureafaciens neuraminidase were superimposed onto the C9-BA-DANA–NEU1
model using the structural alignment algorithm in UCSF Chimera (Petterson et al. 2004) or the
cealign command in PyMOL (version 1.3, Schrodinger, LLC, Cambridge, MA). Amino acid
sequence alignments of the β7–β8 loop of NEU1, -2, -3 and -4 and the three bacterial

neuraminidases were created using PROMALS3D (Pei et al. 2008) and, in the case of C.
perfringens NanI, adjusted based on the structural alignment with NEU1 to account for the
insertion domain beginning after the β7 strand.

C9-BA-DANA inhibition of flagellin-induced increases in total sialidase activity
in mouse lungs
All animal experiments were approved by the University of Maryland Baltimore Institutional
Animal Use and Care Committee. Female BALB/c mice (18–20 g) were obtained from Charles
River Laboratories (Frederick, MD). The mice were intraperitoneally injected with 15 mg/kg of
C9-BA-DANA or DANA dissolved in 25 µL of nonpyrogenic normal saline or saline alone.
After 24 h, mice were intranasally administered flagellin (100 ng/mouse) or the PBS vehicle
alone. At 4 h, the mice were euthanized by CO2 inhalation and cervical dislocation, and the lungs
and kidneys were harvested, weighed and transferred to tubes on ice containing PBS and a
protease inhibitor cocktail (Sigma), and homogenized at 4°C. Lung and kidney homogenates
were centrifuged at 14,000 × g for 10 min at 4°C and supernates were processed for total protein
levels and total sialidase activity for the 4-MU-NANA substrate.

Statistical methods
All values were expressed as mean ± SE. Differences between means were compared using the
Student's t-test or ANOVA followed by the Tukey's multiple range test and considered
significant at P < 0.05. Correlation coefficients (R2) and P values were calculated using
Microsoft Excel.
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